The Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents' (Rameda) SAE revenues saw an increase by 11 percent Y-o-Y, reaching EGP 894 million in FY2018/2019, according to the company's earnings release.
The growth in revenue, according to the statement, was driven mainly by the overall improvement in average selling prices.
In the fourth quarter of 2019, total revenues stood at EGP 275.2 million, up 17.9 percent Y-o-Y, while gross profit recorded EGP 405.6 million, representing a gross profit margin of 45.4 percent, down from 50.3 percent in FY2017/2018.
Gross profit came in at EGP 144 million in the fourth quarter of 2019, up 13.1 percent Y-o-Y.
Rameda's earnings before interest, taxes, depreciation and amortisation (EBITDA) recorded EGP 260.9 million in FY 2018/2019, down by 9.7 percent Y-o-Y and yielding an adjusted EBITDA margin of 29.2 percent.
In the fourth quarter of 2019, adjusted EBITDA came in at EGP 101.6 million, up 4.2 percent Y-o-Y.